Decoy Therapeutics Inc.
DCOY
$2.99
$0.010.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1,020.53% | -- | -- | -- | -- |
| Gross Profit | -825.00% | -- | -- | -- | -- |
| SG&A Expenses | -20.85% | -35.14% | -31.78% | 12.66% | -0.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.39% | -24.60% | -34.30% | 6.74% | -15.76% |
| Operating Income | -7.38% | 24.60% | 34.30% | -6.74% | 15.76% |
| Income Before Tax | -183.14% | -134.00% | -124.52% | -0.22% | 21.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -183.14% | -134.00% | -124.52% | -0.22% | 21.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -183.14% | -134.00% | -124.52% | -0.22% | 21.05% |
| EBIT | -7.38% | 24.60% | 34.30% | -6.74% | 15.76% |
| EBITDA | -7.04% | 24.74% | 34.37% | -6.75% | 15.71% |
| EPS Basic | -25.38% | -1,974.85% | -4,058.40% | -- | -- |
| Normalized Basic EPS | 88.73% | -1,309.33% | -1,241.27% | -- | -- |
| EPS Diluted | -25.38% | -1,974.85% | -4,058.40% | -- | -- |
| Normalized Diluted EPS | 88.73% | -1,309.33% | -1,241.27% | -- | -- |
| Average Basic Shares Outstanding | 336.54% | 189.89% | 23.44% | -- | -- |
| Average Diluted Shares Outstanding | 124.04% | 46.79% | 127.13% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |